Loading
Rapid Micro Biosystems, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by PEI MELINDA LITHERLAND, was filed 05 Dec 2024.
Rapid Micro Biosystems, Inc.: what insiders have been doing
Every trade that managers of Rapid Micro Biosystems, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 21 October 2025 to 21 October 2026, the disclosure feed for Rapid Micro Biosystems, Inc. logged 24 filings by 9 insiders.
All open-market trades in the period are sales: 10 sales worth €565k, by 4 insiders, with no purchase on record. One trade stands out by size: a sale of €161k from Longitude Capital Partners II, LLC, disclosed on 6 February 2026.
With 24 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Our records for Rapid Micro Biosystems, Inc. go back to 2021, with 16 purchases and 10 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 33.6 m USD of revenue and -47.1 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
103
Thresholds
n/a
Buy Volume
€478,208
16 ops. · all time
Sell Volume
€564,766
10 ops. · all time
Who traded when
BuySaleRobert G. Spignesi Jr.3 sales
Sean M. Wirtjes3 sales
Wilson John J. Addington3 sales
Pei Melinda Litherland2 buys
Longitude Capital Partners II, LLC1 sale
Since the insiders bought
- +279.0%Entry US$1.05 · Close at T+365 US$3.98
- +292.8%Entry US$0.83 · Close at T+365 US$3.26
- +283.5%Entry US$0.85 · Close at T+365 US$3.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 26,257 of 26,281 companies
2.3
score / 100
Value2
Quality3
FCF yld-82%
Earn yld-121%
EV/EBITDA·
ROE-142%
Gross mgn3.1%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.85
Analyst consensus
4 analysts1.00/5
US$3.00Target US$5.75(+580%)US$8.00
Income statement
RevenueUS$33.6M
Gross profitUS$1M3% margin
EBITDA-US$42.7M-127% margin
Net income-US$47.1M-145.6% margin
Valuation
PER (forward)-1.2x
P/Book2.4x
Beta1.51
Balance sheet & cash
Market capUS$42.4M
Total debtUS$23.9M
Free Cash Flow-US$31.9M
Debt / Equity132%
Profitability & ownership
ROE-141.6%
ROA-46.4%
% insiders10.1%
% institutions46.1%
Last declaration on 24 July 2026
Declarations103 total
1,681 shares@ US$0.750.0023% mcap2.1% of flowClass A Common StockSEC:0001415666-26-000008:0
1,402 shares@ US$0.750.0019% mcap0.2% of flowClass A Common StockSEC:0001853904-26-000020:0
1,827 shares@ US$0.750.0025% mcap2.3% of flowClass A Common StockSEC:0001415666-26-000008:1
10,000 shares@ US$1.70440.031% mcap8.2% of flowClass ASEC144:0001959173-26-005162
6,312 shares@ US$1.750.020% mcap5.3% of flowClass ASEC144:0001959173-26-005011
3,688 shares@ US$1.750.0063% mcap3.1% of flowClass ASEC144:0001959173-26-004811
5,000 shares@ US$1.86980.0092% mcap4.4% of flowClass ASEC144:0001959173-26-004536
19,300 shares0Class A Common StockSEC:0002070373-26-000003:0
9,603 shares@ US$4.318119.5% of flowClass A Common StockSEC:0001872301-26-000012:0
17,922 shares@ US$4.111512.5% of flowClass A Common StockSEC:0001853904-26-000013:0
7,480 shares@ US$4.318114.5% of flowClass A Common StockSEC:0001289733-26-000011:0
842 shares@ US$0.75100.0% of flowClass A Common StockSEC:0001107158-26-000002:0
5,403 shares@ US$3.9239.8% of flowClass A Common StockSEC:0001872301-26-000009:0
38,327 shares@ US$3.885325.0% of flowClass A Common StockSEC:0001853904-26-000010:0
17,254 shares@ US$3.92329.9% of flowClass A Common StockSEC:0001289733-26-000008:0
74,000 shares0Class A Common StockSEC:0001380106-26-000017:0
97,000 shares0Class A Common StockSEC:0001380106-26-000015:0
264,000 shares0Class A Common StockSEC:0001380106-26-000013:0
4,610 shares@ US$3.78278.1% of flowClass A Common StockSEC:0001872301-26-000005:0
12,840 shares@ US$3.78278.1% of flowClass A Common StockSEC:0001853904-26-000004:0
6,027 shares@ US$3.782710.0% of flowClass A Common StockSEC:0001289733-26-000004:0
49,000 shares@ US$3.879485.7% of flowClass A Common StockSEC:0001193125-26-041248:0
629,032 shares@ US$0.0514.3% of flowClass A Common StockSEC:0001193125-26-036387:0
40,000 shares0Class A Common StockSEC:0001380106-25-000203:0
3,400 shares@ US$0.750.4% of flowClass A Common StockSEC:0001380106-25-000190:0
25 of 103 declarations
About Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems, Inc. is a U.S.-based life sciences technology company listed on the Nasdaq under the ticker RPID in the United States. The company operates in a specialized segment of healthcare manufacturing automation: microbial quality control (“MQC”) testing for pharmaceutical and biopharmaceutical production. Its core end markets include biologics, vaccines, cell and gene therapies, and sterile injectables, where speed, data integrity, and regulatory compliance are critical.
Founded in 2006 and incorporated in Delaware, Rapid Micro Biosystems built its business around the Growth Direct® platform, a proprietary system designed to automate historically manual and error-prone microbiology workflows. The platform modernizes routine QC testing such as environmental monitoring, water testing, and bioburden testing. By bringing QC automation closer to the manufacturing floor, the system is intended to reduce release-cycle time, improve accuracy, enhance data integrity, and lower the operational risk associated with contamination events and production downtime. For investors, the appeal is that this is a mission-critical application rather than a discretionary tool: once embedded in a manufacturing network, the platform can become part of a customer’s long-term quality infrastructure.
Read moreShow less
The company is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts, and international locations in Switzerland, Germany, and the Netherlands. That footprint reflects a commercial model aimed at global pharmaceutical and biotech customers with multi-site manufacturing operations. Rapid Micro Biosystems has also emphasized recurring revenue from consumables and service contracts, which is important because it can create a more durable revenue stream than one-off system placements alone.
In competitive terms, Rapid Micro Biosystems occupies a narrow but differentiated niche at the intersection of automation, microbiology, and regulated manufacturing. Its value proposition is centered on replacing slow manual testing with a growth-based automated platform that can improve efficiency, throughput, compliance, and decision-making. Recent company disclosures indicate continued traction with large global customers. In March 2026, management reported record fourth-quarter and full-year 2025 results and issued 2026 guidance calling for higher revenue and more Growth Direct placements. The company also highlighted significant multi-system orders from Amgen and Samsung Biologics, which is notable because it suggests expanding enterprise-level adoption rather than isolated pilot use. Overall, Rapid Micro Biosystems remains a specialized growth story on Nasdaq in the United States, with meaningful exposure to biopharma capital spending, recurring consumables, and the gradual automation of quality control workflows across large manufacturing networks.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
